The group's pulmonary arterial hypertension therapy might work in sicker patients, but investors are unwilling to stick around.
The pharma giant leads the pulmonary arterial hypertension pipeline, but other potentially disease-modifying treatments are in the works.
Aprocitentan’s effect size falls short of expectations, raising the risk that J&J might cool on its Idorsia partnership, while Cincor remains one to watch.
The company’s renal denervation system has failed in a crucial late-stage trial, just as an earlier version did eight years ago.
With a mid-stage win in cholesterol lowering in the bag, attention turns to obesity.
Buying Abiomed for $17bn sharpens the group’s focus, somewhat unexpectedly, on cardiovascular tech.